LIGHT, also termed tumor necrosis factor superfamily member 14 (TNFSF14), has been widely reported in a range of malignancies, including non-small-cell lung cancer (NSCLC) (Brunetti et al., 2020), multiple myeloma (Brunetti et al., 2014; Brunetti et al., 2018), colorectal cancer (Qin et al., 2013; Maker et al., 2015; Qiao et al., 2017), prostate tumor (Yan et al., 2015), breast cancer (Gantsev et al., 2013), and melanoma (Hehlgans and Männel, 2001). Here, TNFSF14 is linked to AL amyloidosis.